Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

18.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.8K
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

472
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
472
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

14
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
14
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

73
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
73

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.

Leukemia & lymphoma·2026
Same author

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same author

A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.

Current medical research and opinion·2026
Same author

Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma.

American journal of hematology·2026
Same author

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Blood·2026
Same author

Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma.

JCI insight·2026

Related Experiment Video

Updated: Apr 19, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

1.1K

Asymptomatic monoclonal gammopathies.

Claire Bories1, Sundar Jagannath2

  • 1Service des Maladies du Sang, CHRU Lille, France.

Clinical Lymphoma, Myeloma & Leukemia
|December 10, 2014
PubMed
Summary

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are early plasma cell disorders. Current definitions may not accurately identify high-risk patients needing treatment, potentially leading to overtreatment.

Keywords:
MGUSPrognosisRisk stratificationSmoldering MyelomaTreatment of high-risk smoldering myeloma

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.9K
Analysis of Somatic Hypermutation in the JH4 intron of Germinal Center B cells from Mouse Peyer's Patches
09:35

Analysis of Somatic Hypermutation in the JH4 intron of Germinal Center B cells from Mouse Peyer's Patches

Published on: April 20, 2021

7.5K

Related Experiment Videos

Last Updated: Apr 19, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

1.1K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.9K
Analysis of Somatic Hypermutation in the JH4 intron of Germinal Center B cells from Mouse Peyer's Patches
09:35

Analysis of Somatic Hypermutation in the JH4 intron of Germinal Center B cells from Mouse Peyer's Patches

Published on: April 20, 2021

7.5K

Area of Science:

  • Hematology
  • Oncology

Background:

  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are precursor conditions to plasma cell dyscrasias.
  • These conditions are defined by the presence of a malignant clone without end-organ damage, carrying a risk of progression to symptomatic disease.

Purpose of the Study:

  • To review current definitions, prognostic factors, and risk stratification for asymptomatic gammopathies.
  • To discuss clinical trial outcomes for high-risk SMM patients.
  • To highlight the need for updated definitions incorporating advanced diagnostics.

Main Methods:

  • Review of existing literature on MGUS and SMM.
  • Analysis of current diagnostic criteria and prognostic indicators.
  • Discussion of imaging and genomic advancements in risk assessment.

Main Results:

  • MGUS progresses at ~1% per year; SMM progresses at 10% in the first 5 years.
  • Current definitions may not adequately identify patients at high risk of rapid progression.
  • There is a risk of overtreatment in patients who do not require immediate therapy.

Conclusions:

  • Existing definitions for MGUS and SMM require revision to include advanced imaging and genomic data.
  • Accurate risk stratification is crucial to avoid unnecessary treatment in low-risk patients.
  • Further research and updated guidelines are needed for optimal management of asymptomatic plasma cell dyscrasias.